fashion -WSS

fashion

author：explore 2025-10-04 04:00:36 - browse：6

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Johnson & Johnson sues to stop Medicare negotiation

knowledge

WSS

How one medical school became remarkably diverse

FDA approval of Sarepta Duchenne genetic therapy gives me hope

New air purifier tech could be key to improving indoor air quality

Tori Bowie and the unacceptable rates of Black maternal death

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Supreme Court strikes down use of affirmative action

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

After affirmative action ruling, medical educators look to 'holistic review'

United colonoscopy coverage change 'may cost lives,' doctors say

More hospitals are billing patients as online messages surge

The cancer drug shortage isn’t new — and neither are the solutions

Walensky prepares to leave CDC — and Congress — behind

As demand for Covid shots wanes, Moderna seeks its next success

A look at other Americans who have crossed into North Korea over the years

Wildfire smoke exposes gaps in outdoor worker protections

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Why you get paid to donate plasma but not blood

How one medical school became remarkably diverse

Flagship, Pfizer team up in deal worth up to $7 billion

New air purifier tech could be key to improving indoor air quality

Hepatitis C has a cure — but many Americans still lack access to it

hotspot

focus

knowledge

focus